{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:47:12Z","timestamp":1773798432031,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00467-015-3208-1","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T11:20:23Z","timestamp":1443525623000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis"],"prefix":"10.1007","volume":"31","author":[{"given":"Radwa","family":"El Borolossy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamia Mohamed","family":"El Wakeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihab","family":"El Hakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagwa","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"3208_CR1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/cvr\/cvs240","volume":"96","author":"I Six","year":"2012","unstructured":"Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, Slama M (2012) Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 96:130\u2013139","journal-title":"Cardiovasc Res"},{"key":"3208_CR2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","volume":"12","author":"SK Ganesh","year":"2001","unstructured":"Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK (2001) Association of elevated serum PO4, Ca * PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131\u20132139","journal-title":"J Am Soc Nephrol"},{"key":"3208_CR3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607\u2013624","journal-title":"Am J Kidney Dis"},{"key":"3208_CR4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1681\/ASN.2007070760","volume":"19","author":"S Mathew","year":"2008","unstructured":"Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA (2008) The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 19:1092\u20131105","journal-title":"J Am Soc Nephrol"},{"key":"3208_CR5","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/j.1523-1755.2005.00651.x","volume":"68","author":"A Levin","year":"2005","unstructured":"Levin A, Li YC (2005) Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease. Kidney Int 68:1973\u20131981","journal-title":"Kidney Int"},{"key":"3208_CR6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","volume":"362","author":"M Tonelli","year":"2010","unstructured":"Tonelli M, Pannu N, Manns B (2010) Oral phosphate binders in patients with kidney failure. N Engl J Med 362:1312\u20131324","journal-title":"N Engl J Med"},{"key":"3208_CR7","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrneph.2011.112","volume":"7","author":"AJ Hutchison","year":"2011","unstructured":"Hutchison AJ, Smith CP, Brenchley PE (2011) Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 7:578\u2013589","journal-title":"Nat Rev Nephrol"},{"key":"3208_CR8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407\u20131415","journal-title":"J Am Soc Nephrol"},{"key":"3208_CR9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1523-1755.2004.00877.x","volume":"66","author":"B Manns","year":"2004","unstructured":"Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M (2004) A systematic review of sevelamer in ESRD and ananalysis of its potential economic impact in Canada and the United States. Kidney Int 66:1239\u20131247","journal-title":"Kidney Int"},{"key":"3208_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40268-013-0024-6","volume":"13","author":"A Lenglet","year":"2013","unstructured":"Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy Z (2013) Use of nicotinamide to treat hyperphosphatemia in dialysis patients. Drugs R&D 13:165\u2013173","journal-title":"Drugs R&D"},{"key":"3208_CR11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0025-6196(12)60393-0","volume":"67","author":"T O\u2019Brien","year":"1992","unstructured":"O\u2019Brien T, Silverberg J, Nguyen T (1992) Nicotinic acid induced toxicity associated with cytopenia and decrease level of thyroxin-binding globulin. Mayo Clin Proc 67:465\u2013468","journal-title":"Mayo Clin Proc"},{"key":"3208_CR12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ndt\/14.5.1195","volume":"14","author":"K Katai","year":"1999","unstructured":"Katai K, Tanaka H, Tatsumi S (1999) Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 14:1195\u20131201","journal-title":"Nephrol Dial Transplant"},{"key":"3208_CR13","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI110163","volume":"67","author":"SA Kempson","year":"1981","unstructured":"Kempson SA, Colon-Otero G, Ou SY, Turner ST, Dousa TP (1981) Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 67:1347\u20131360","journal-title":"J Clin Invest"},{"key":"3208_CR14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2215\/CJN.07341009","volume":"5","author":"D Maccubbin","year":"2010","unstructured":"Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG (2010) Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 5:582\u2013589","journal-title":"Clin J Am Soc Nephrol"},{"key":"3208_CR15","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/ndt\/gfh781","volume":"20","author":"N Eto","year":"2005","unstructured":"Eto N, Miyata Y, Ohno H, Yamashita T (2005) Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with a renin-induced renal failure. Nephrol Dial Transplant 20:1378\u20131384","journal-title":"Nephrol Dial Transplant"},{"key":"3208_CR16","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","volume":"65","author":"Y Takahashi","year":"2004","unstructured":"Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N (2004) Nicotinamide suppress hyperphosphatemia in hemodialysis patients. Kidney Int 65:1099\u20131104","journal-title":"Kidney Int"},{"key":"3208_CR17","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1681\/ASN.2009050559","volume":"20","author":"Y Sabbagh","year":"2009","unstructured":"Sabbagh Y, O\u2019Brien SP, Song W, Boulanger JH, Stockmann A, Arbeeny C (2009) Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20:2348\u20132358","journal-title":"J Am Soc Nephrol"},{"key":"3208_CR18","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2011121213","volume":"23","author":"SC Schiavi","year":"2012","unstructured":"Schiavi SC, Tang W, Bracken C, O\u2019Brien SP, Song W, Boulanger J (2012) Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 23:1691\u20131700","journal-title":"J Am Soc Nephrol"},{"key":"3208_CR19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","volume":"3","author":"SC Cheng","year":"2008","unstructured":"Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW (2008) A randomized, double-blind, placebo-controlled trail of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 3:1131\u20131138","journal-title":"Clin J Am Soc Nephrol"},{"key":"3208_CR20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/089686080902900515","volume":"29","author":"DO Young","year":"2009","unstructured":"Young DO, Cheng SC, Delmez JA, Coyne DW (2009) The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 29:562\u2013567","journal-title":"Perit Dial Int"},{"key":"3208_CR21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11255-006-0001-x","volume":"38","author":"K Sampathkumar","year":"2006","unstructured":"Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S, Ajeshkumar RN (2006) Extended release nicotinic acid: a novel oral agent for phosphate control. Int Urol Nephrol 38:171\u2013174","journal-title":"Int Urol Nephrol"},{"key":"3208_CR22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4103\/0971-4065.83735","volume":"21","author":"J Vasantha","year":"2011","unstructured":"Vasantha J, Soundararajan P, Vanitharani N, Kannan G, Thennarasu P, Neenu G (2011) Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. Indian J Nephrol 21:245\u2013249","journal-title":"Indian J Nephrol"},{"key":"3208_CR23","first-page":"58","volume":"31","author":"H Shahbazian","year":"2011","unstructured":"Shahbazian H, Mohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, Hayati F (2011) Oral nicotinamide reduces serum level of phosphorus, increase HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind, randomized clinical trial. Nefrologia 31:58\u201365","journal-title":"Nefrologia"},{"key":"3208_CR24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2215\/CJN.01470307","volume":"2","author":"D Muller","year":"2007","unstructured":"Muller D, Mehling H, Otto B, Otto B, Bergmann-Lips R, Luft F, Jordan J (2007) Niacin lowers serum phosphorus and increases HDL cholesterol in dialysis patients. Clin J Am Soc Nephrol 2:1249\u20131254","journal-title":"Clin J Am Soc Nephrol"},{"key":"3208_CR25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s001250051536","volume":"43","author":"M Knip","year":"2000","unstructured":"Knip M, Douek IF, Moore WP, Gillmor HA, McLean AEM, Bingley PJ (2000) Safety of high doses nicotinamide: a review. Diabetologia 43:1337\u20131345","journal-title":"Diabetologia"},{"key":"3208_CR26","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/j.1523-1755.2005.00583_8.x","volume":"68","author":"J Rottembourg","year":"2005","unstructured":"Rottembourg J, Launay-Vacher V, Massard J (2005) Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 68:2911\u20132912","journal-title":"Kidney Int"},{"key":"3208_CR27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(04)15786-3","volume":"363","author":"E Gale","year":"2004","unstructured":"Gale E, Bingley P, Emmett C, Collier T (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT) Group: a randomized controlled trial of intervention before the onset of type 1 diabetes. Lancet 363:925\u2013931","journal-title":"Lancet"},{"key":"3208_CR28","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/sj.ki.5000381","volume":"69","author":"P Delanaye","year":"2006","unstructured":"Delanaye P, Weekers L, Krzesinski J (2006) Diarrhea induced by high doses of nicotinamide in dialysis patients. Kidney Int 69:1914","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-015-3208-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-015-3208-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-015-3208-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T12:05:22Z","timestamp":1653221122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-015-3208-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3208"],"URL":"https:\/\/doi.org\/10.1007\/s00467-015-3208-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}